Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients
about
Antibiotic strategies in the era of multidrug resistancePrevalence and emergence of carbapenemases-producing Gram-negative bacteria in Mediterranean basin.Antibiotic stewardship in the intensive care unit.Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study.Epinecidin-1 has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsisComorbidities and disease severity as risk factors for carbapenem-resistant Klebsiella pneumoniae colonization: report of an experience in an internal medicine unit.Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.Treatment of bloodstream infections in ICUsComparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.Characterising the Transmission Dynamics of Acinetobacter baumannii in Intensive Care Units Using Hidden Markov ModelsMechanisms of antimicrobial resistance in Gram-negative bacilli.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Disruption of the microbiota across multiple body sites in critically ill childrenVery high prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in bacteriemic patients hospitalized in teaching hospitals in Bamako, Mali.Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.Costs associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France.Rates of gastrointestinal tract colonization of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa in hospitals in Saudi ArabiaRisk Factors and Outcomes for Intestinal Carriage of AmpC-Hyperproducing Enterobacteriaceae in Intensive Care Unit Patients.Bloodstream infections in the Intensive Care Unit.Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.KlebSeq, a Diagnostic Tool for Surveillance, Detection, and Monitoring of Klebsiella pneumoniaeTreatment of febrile geriatric patients with suspected urinary tract infections in a hospital with high rates of ESBL producing bacteria: a cohort study.Relation between presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens in ICU patients.Antimicrobial stewardship of β-lactams in intensive care units.Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).The emerging threat of multidrug-resistant Gram-negative bacteria in urology.Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE).Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.The use and risks of antibiotics in critically ill patients.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy.Clinical metagenomics for the management of hospital- and healthcare-acquired pneumonia.Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum β-lactamase-producing Enterobacteriaceae.A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.Prevalence, antimicrobial susceptibility, and genetic diversity of Pseudomonas aeruginosa as intestinal colonizer in the community.Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis.Comment on: National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries.
P2860
Q26744091-446B158A-A15D-420C-B657-005B3C15C44BQ30249131-0BE05EEF-9D8A-490B-B7DC-8FCE42DF1A86Q30408712-D24F0D39-1295-4B66-9226-360D628790E4Q33846503-E3BBC2FC-B49A-471F-8273-DAC3304F2533Q34058050-183B267A-4B51-42ED-8A49-CEFE0D96CBB3Q34343968-E427A058-9DFE-4EC5-999D-E4A807FC1F86Q34596344-56E91DFD-F191-4E76-9B7D-8211A24F7063Q34896896-ECA5E97D-D363-4D64-8615-F5B0D3AC5441Q35552650-161A908A-A1F8-40EE-9010-2789B249FDB3Q35679653-5830E60A-61D8-4309-9A0E-D18925B114F7Q35935319-B11DD59E-85D9-4BC1-BB14-94E6663DFF71Q36078359-A5584F14-57ED-428F-AC74-865732EC733EQ36235947-155FB492-0C26-46C0-8AE4-27597DA30E4BQ36292839-3457C2B7-3815-40C4-88E5-1951895AA13AQ36438937-7F30D793-D5CC-4D52-9376-BAC064A6E05BQ36526872-5D0D8188-7E52-45DC-8541-D01FBC6F4B8BQ36613734-CE3C3FF1-67E6-4DAC-A2E8-A6CEDB5D464DQ36644601-3E51D6E9-2355-4DFC-88E4-AADF9F95C85AQ36913336-CEF624EA-13AB-48C8-9495-6D2BAEFB3FFFQ37205420-0F308243-D3D1-49B1-A392-DB34CFF89308Q37280606-87A4A57B-D42B-420F-8D48-3F0FADC3C359Q37517046-9125FF19-A658-4E3F-B7A5-659C0E6C6A9BQ37622014-3F5050B4-1018-4E19-A29E-961B1BBFD441Q38198157-D263E5B3-3EAA-4B1B-B0C3-9196B78C22CFQ38528292-32B00B25-7345-4A41-8C82-52541D0B4613Q38579512-7BFD5A5F-54DF-40BB-8761-1EFBB6D50844Q38624963-ED124300-3865-41AD-A6FF-F7356FEFAE3EQ38626553-D0B88821-3474-4BFB-B9C5-06AEAB15C753Q38679343-02FB7E9E-1BC0-4422-8454-C1B3310FB6A0Q38739545-474378FD-0963-4EE5-8CEB-C9D3A3BAD866Q38767901-6A751DBA-F909-4C46-B9B3-057F9F953A95Q38792841-AC911440-4927-4C8B-9933-A4799816F7D9Q38815453-ACE8C704-2AA4-4386-8909-1080FDF75043Q38901011-E6A9257E-C625-4849-83A4-DF1CB072B895Q40119449-F4BFA44C-3E6C-463D-910F-0CE395D6085BQ40174829-DA49DC07-0AB8-47A8-959A-172D388741BFQ40630989-1AC9E3EE-EEF1-451C-ABDE-8D381F20611FQ41127249-2C0A148C-67B3-4988-9AAC-3D2D4BB477E8Q41544896-EAEA5FBD-9DFF-4930-9D3C-71D8CB7E8C57Q41992899-BAA6CCB6-9EE8-448F-8806-2C23BB97D0BA
P2860
Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Emergence of imipenem-resistan ...... ora of intensive care patients
@ast
Emergence of imipenem-resistan ...... ora of intensive care patients
@en
type
label
Emergence of imipenem-resistan ...... ora of intensive care patients
@ast
Emergence of imipenem-resistan ...... ora of intensive care patients
@en
prefLabel
Emergence of imipenem-resistan ...... ora of intensive care patients
@ast
Emergence of imipenem-resistan ...... ora of intensive care patients
@en
P2093
P2860
P50
P356
P1476
Emergence of imipenem-resistan ...... ora of intensive care patients
@en
P2093
Antoine Andremont
Assiya El Mniai
Emilie Hamelet
François Barbier
Gilles Defrance
Jean-Christophe Lucet
Laurence Armand-Lefèvre
Michel Wolff
Patrick Plésiat
Philippe Montravers
P2860
P304
P356
10.1128/AAC.01823-12
P407
P577
2013-01-14T00:00:00Z